Triad Financial Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$642K Buy
1,196
+73
+7% +$37.6K 0.23% 43
2023
Q2
$527K Sell
1,123
-54
-5% -$22.6K 0.22% 47
2023
Q1
$404K Sell
1,177
-2
-0.2% -$675 0.18% 52
2022
Q4
$431K Buy
1,179
+7
+0.6% +$2.48K 0.19% 58
2022
Q3
$379K Buy
1,172
+27
+2% +$8.55K 0.21% 54
2022
Q2
$371K Buy
1,145
+29
+3% +$8.71K 0.21% 61
2022
Q1
$320K Buy
1,116
+55
+5% +$14.2K 0.17% 74
2021
Q4
$293K Buy
+1,061
New +$269K 0.17% 87

Other funds holding LLY

Triad Financial Advisors's LLY Position: Q3 2023 in Review

Triad Financial Advisors increased its Eli Lilly (LLY) stake by 6.5% in Q3 2023, buying an estimated $37.6K and bringing the position to 1,196 shares worth $642K. The position accounts for 0.23% of the portfolio, ranked #43.

Triad Financial Advisors first reported a position in LLY in Q4 2021 and has held it in 8 quarters since. 2,974 funds tracked by Wall St. Rank hold LLY as of Q3 2023.

  • Triad Financial Advisors held 1,196 shares of Eli Lilly worth $642K as of Q3 2023.
  • Triad Financial Advisors bought 73 Eli Lilly shares in Q3 2023, an estimated $37.6K.
  • Eli Lilly made up 0.23% of Triad Financial Advisors's portfolio in Q3 2023, its #43 holding.
  • Triad Financial Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 8 quarters since.
  • 2,974 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2023.

Based on Triad Financial Advisors's 13F filing for Q3 2023, filed 2 Nov 2023.